CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer

Abstract Background Ferroptosis is a novel mode of non-apoptotic cell death induced by build-up of toxic lipid peroxides (lipid-ROS) in an iron dependent manner. Cancer-associated fibroblasts (CAFs) support tumor progression and drug resistance by secreting various bioactive substances, including ex...

Full description

Bibliographic Details
Main Authors: Haiyang Zhang, Ting Deng, Rui Liu, Tao Ning, Haiou Yang, Dongying Liu, Qiumo Zhang, Dan Lin, Shaohua Ge, Ming Bai, Xinyi Wang, Le Zhang, Hongli Li, Yuchong Yang, Zhi Ji, Hailong Wang, Guoguang Ying, Yi Ba
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Molecular Cancer
Subjects:
GC
Online Access:http://link.springer.com/article/10.1186/s12943-020-01168-8
id doaj-0f7fec71076041c089b993d3f0940378
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Haiyang Zhang
Ting Deng
Rui Liu
Tao Ning
Haiou Yang
Dongying Liu
Qiumo Zhang
Dan Lin
Shaohua Ge
Ming Bai
Xinyi Wang
Le Zhang
Hongli Li
Yuchong Yang
Zhi Ji
Hailong Wang
Guoguang Ying
Yi Ba
spellingShingle Haiyang Zhang
Ting Deng
Rui Liu
Tao Ning
Haiou Yang
Dongying Liu
Qiumo Zhang
Dan Lin
Shaohua Ge
Ming Bai
Xinyi Wang
Le Zhang
Hongli Li
Yuchong Yang
Zhi Ji
Hailong Wang
Guoguang Ying
Yi Ba
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
Molecular Cancer
Ferroptosis
Cancer-associated fibroblasts
Exosomes
miR-522
GC
author_facet Haiyang Zhang
Ting Deng
Rui Liu
Tao Ning
Haiou Yang
Dongying Liu
Qiumo Zhang
Dan Lin
Shaohua Ge
Ming Bai
Xinyi Wang
Le Zhang
Hongli Li
Yuchong Yang
Zhi Ji
Hailong Wang
Guoguang Ying
Yi Ba
author_sort Haiyang Zhang
title CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
title_short CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
title_full CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
title_fullStr CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
title_full_unstemmed CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
title_sort caf secreted mir-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
publisher BMC
series Molecular Cancer
issn 1476-4598
publishDate 2020-02-01
description Abstract Background Ferroptosis is a novel mode of non-apoptotic cell death induced by build-up of toxic lipid peroxides (lipid-ROS) in an iron dependent manner. Cancer-associated fibroblasts (CAFs) support tumor progression and drug resistance by secreting various bioactive substances, including exosomes. Yet, the role of CAFs in regulating lipid metabolism as well as ferroptosis of cancer cells is still unexplored and remains enigmatic. Methods Ferroptosis-related genes in gastric cancer (GC) were screened by using mass spectrum; exosomes were isolated by ultra-centrifugation and CAF secreted miRNAs were determined by RT-qPCR. Erastin was used to induce ferroptosis, and ferroptosis levels were evaluated by measuring lipid-ROS, cell viability and mitochondrial membrane potential. Results Here, we provide clinical evidence to show that arachidonate lipoxygenase 15 (ALOX15) is closely related with lipid-ROS production in gastric cancer, and that exosome-miR-522 serves as a potential inhibitor of ALOX15. By using primary stromal cells and cancer cells, we prove that exosome-miR-522 is mainly derived from CAFs in tumor microenvironment. Moreover, heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) was found to mediate miR-522 packing into exosomes, and ubiquitin-specific protease 7 (USP7) stabilizes hnRNPA1 through de-ubiquitination. Importantly, cisplatin and paclitaxel promote miR-522 secretion from CAFs by activating USP7/hnRNPA1 axis, leading to ALOX15 suppression and decreased lipid-ROS accumulation in cancer cells, and ultimately result in decreased chemo-sensitivity. Conclusions The present study demonstrates that CAFs secrete exosomal miR-522 to inhibit ferroptosis in cancer cells by targeting ALOX15 and blocking lipid-ROS accumulation. The intercellular pathway, comprising USP7, hnRNPA1, exo-miR-522 and ALOX15, reveals new mechanism of acquired chemo-resistance in GC. Graphical abstract
topic Ferroptosis
Cancer-associated fibroblasts
Exosomes
miR-522
GC
url http://link.springer.com/article/10.1186/s12943-020-01168-8
work_keys_str_mv AT haiyangzhang cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT tingdeng cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT ruiliu cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT taoning cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT haiouyang cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT dongyingliu cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT qiumozhang cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT danlin cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT shaohuage cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT mingbai cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT xinyiwang cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT lezhang cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT honglili cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT yuchongyang cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT zhiji cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT hailongwang cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT guoguangying cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
AT yiba cafsecretedmir522suppressesferroptosisandpromotesacquiredchemoresistanceingastriccancer
_version_ 1724435379461816320
spelling doaj-0f7fec71076041c089b993d3f09403782020-11-25T04:04:45ZengBMCMolecular Cancer1476-45982020-02-0119111710.1186/s12943-020-01168-8CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancerHaiyang Zhang0Ting Deng1Rui Liu2Tao Ning3Haiou Yang4Dongying Liu5Qiumo Zhang6Dan Lin7Shaohua Ge8Ming Bai9Xinyi Wang10Le Zhang11Hongli Li12Yuchong Yang13Zhi Ji14Hailong Wang15Guoguang Ying16Yi Ba17Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and TherapyAbstract Background Ferroptosis is a novel mode of non-apoptotic cell death induced by build-up of toxic lipid peroxides (lipid-ROS) in an iron dependent manner. Cancer-associated fibroblasts (CAFs) support tumor progression and drug resistance by secreting various bioactive substances, including exosomes. Yet, the role of CAFs in regulating lipid metabolism as well as ferroptosis of cancer cells is still unexplored and remains enigmatic. Methods Ferroptosis-related genes in gastric cancer (GC) were screened by using mass spectrum; exosomes were isolated by ultra-centrifugation and CAF secreted miRNAs were determined by RT-qPCR. Erastin was used to induce ferroptosis, and ferroptosis levels were evaluated by measuring lipid-ROS, cell viability and mitochondrial membrane potential. Results Here, we provide clinical evidence to show that arachidonate lipoxygenase 15 (ALOX15) is closely related with lipid-ROS production in gastric cancer, and that exosome-miR-522 serves as a potential inhibitor of ALOX15. By using primary stromal cells and cancer cells, we prove that exosome-miR-522 is mainly derived from CAFs in tumor microenvironment. Moreover, heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) was found to mediate miR-522 packing into exosomes, and ubiquitin-specific protease 7 (USP7) stabilizes hnRNPA1 through de-ubiquitination. Importantly, cisplatin and paclitaxel promote miR-522 secretion from CAFs by activating USP7/hnRNPA1 axis, leading to ALOX15 suppression and decreased lipid-ROS accumulation in cancer cells, and ultimately result in decreased chemo-sensitivity. Conclusions The present study demonstrates that CAFs secrete exosomal miR-522 to inhibit ferroptosis in cancer cells by targeting ALOX15 and blocking lipid-ROS accumulation. The intercellular pathway, comprising USP7, hnRNPA1, exo-miR-522 and ALOX15, reveals new mechanism of acquired chemo-resistance in GC. Graphical abstracthttp://link.springer.com/article/10.1186/s12943-020-01168-8FerroptosisCancer-associated fibroblastsExosomesmiR-522GC